Neurochemical biomarkers to study CNS effects of COVID‐19: A narrative review and synthesis
Arvid Edén(Sahlgrenska University Hospital), Magnus Gisslén(Public Health Agency of Sweden), Joel Simrén(University of Gothenburg), Richard W. Price(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Henrik Zetterberg(University of Wisconsin–Madison)
Cited by 30
Related Papers
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
|Nature Medicine|2019|606
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2022|589